Publications

Publications

Translational biomarker discovery in clinical metabolomics: an introductory tutorial

By:
Contributors: David Broadhurst, PhD

Metabolomics. 2013 Apr;9(2):280-299. Epub 2012 Dec 4.

Xia J1, Broadhurst DI, Wilson M, Wishart DS.

 

Abstract

Metabolomics is increasingly being applied towards the identification of biomarkers for disease diagnosis, prognosis and risk prediction. Unfortunately among the many published metabolomic studies focusing on biomarker discovery, there is very little consistency and relatively little rigor in how researchers select, assess or report their candidate biomarkers. In particular, few studies report any measure of sensitivity, specificity, or provide receiver operator characteristic (ROC) curves with associated confidence intervals. Even fewer studies explicitly describe or release the biomarker model used to generate their ROC curves. This is surprising given that for biomarker studies in most other biomedical fields, ROC curve analysis is generally considered the standard method for performance assessment. Because the ultimate goal of biomarker discovery is the translation of those biomarkers to clinical practice, it is clear that the metabolomics community needs to start “speaking the same language” in terms of biomarker analysis and reporting-especially if it wants to see metabolite markers being routinely used in the clinic. In this tutorial, we will first introduce the concept of ROC curves and describe their use in single biomarker analysis for clinical chemistry. This includes the construction of ROC curves, understanding the meaning of area under ROC curves (AUC) and partial AUC, as well as the calculation of confidence intervals. The second part of the tutorial focuses on biomarker analyses within the context of metabolomics. This section describes different statistical and machine learning strategies that can be used to create multimetabolite biomarker models and explains how these models can be assessed using ROC curves. In the third part of the tutorial we discuss common issues and potential pitfalls associated with different analysis methods and provide readers with a list of nine recommendations for biomarker analysis and reporting. To help readers test, visualize and explore the concepts presented in this tutorial, we also introduce a web-based tool called ROCCET (ROC Curve Explorer & Tester, http://www.roccet.ca). ROCCET was originally developed as a teaching aid but it can also serve as a training and testing resource to assist metabolomics researchers build biomarker models and conduct a range of common ROC curve analyses for biomarker studies.

PubMed

Download PDF

Stay Informed

To stay up to date on all the latest news and publications, subscribe to our newsletter!

APCaRI Registry and Biorepository enrolls 1500th participant – 30% of our goal

We are pleased to announce that the Alberta Prostate Cancer Registry and Biorepository reached 30% of its accrual goal by enrolling participant 1,500! To date more than 100,000 biosamples are stored in the Canadian Research Biorepository along with comprehensive clinical data – all available for cutting edge research.

This was possible thanks to our wonderful team of clinical research personnel, clinicians and partners who have been working collaboratively to reach our goals!

If you are interested in accessing biospecimens or clinical information, let us know at catalina.vasquez@ualberta.ca

Samples available from participants with prostate cancer and age-matched men with negative biopsy
  • Serum (400uL/vial)
  • Plasma (400uL/vial)
  • Buffy Coat (~300uL/vial)
  • Red Blood Cells (400uL/vial)
  • Urine (400uL/vial)
  • Semen (~400uL/vial)
Clinical Information available
  • Demographic information and co-morbidities
  • Family history of prostate cancer
  • Pathology and diagnosis details
  • Clinical and pathological staging
  • Treatment history
  • Outcomes
  • Biospecimen collection, sample availability and processing details
- Unknown